Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis.

Jia A, Yang M, Wang T, Hua Y, Lu H

Frontiers in cardiovascular medicine3 Oct 2025Cited by 2 (Europe PMC)

PMID41112222PMCIDPMC12533278DOI10.3389/fcvm.2025.1633114PepBankPUB-41112222

Summary

ObjectiveTo investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).MethodA systematic search was performed in 3 databases (Pubmed, Embase, and Cochrane Library) for articles evaluating the effectiveness and safety of GLP-1RAs (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) for the treatment of obese patients with CHF from the time the database was created until 5 January 2025. Meta-analyses were performed to evaluate: primary outcomes, including all-cause mortality, cardiovascular mortality, and worsening heart failure events; secondary outcomes, encompassing changes in body weight, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk distance, B-type Natriuretic Peptide (BNP) level, high-sensitivity C-Reactive Protein (hs-CRP) level, and left ventricular ejection fraction (LVEF) level; and safety outcomes, specifically gastrointestinal adverse events and serious adverse events.ResultsA total of 6 papers were included for Meta-analysis. The primary clinical outcomes: all-cause mortality [OR=0.89, 95% confidence interval (CI): 0.40-2.00, p = 0.78], cardiovascular mortality (OR = 0.93, 95% CI: 0.22-4.00, p = 0.92) and worsening heart failure events (OR=0.43, 95% CI: 0.30-0.59, p < 0.00001); For secondary outcomes, change in body weight (MD = -7.90, 95% CI: -15.44 to -0.35, p = 0.04), change in the KCCQ-CSS (MD = 6.81, 95% CI: 6.62-6.99, p < 0.00001),change in the 6-minute walk distance (MD = 15.91, 95% CI: 15.36-16.47, p < 0.00001), change in the BNP level (MD = -0.13, 95% CI: -0.21 to -0.05, p = 0.001), changes in the hs-CRP level (MD = -16.61, 95% CI: -48.53 to 15.31, p = 0.31) and change in the LVEF level (MD = -0.91, 95% CI: -2.12 to 0.29, p = 0.14). For safety outcomes, gastrointestinal adverse events (OR=0.87, 95% CI: 0.11-7.05, p = 0.90) and serious adverse events (OR=0.63, 95% CI: 0.37-1.08, p = 0.09).ConclusionThe study results show that GLP-1RAs significantly reduce the risk of worsening heart failure events and improve cardiac function, suggesting that GLP-1RAs are promising treatment options for obese patients with CHF.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study33

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone33

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change all-cause mortality.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change deaths from any cause.
Peptide
Liraglutide
Outcome
No significant changeAll-cause mortality
Study
n: not reported in source
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Measurements
Odds ratio
0.89 ratio
all-cause mortality
Source sentences
Summary
all-cause mortality [OR=0.89, 95% confidence interval (CI): 0.40-2.00, p = 0.78]
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222201
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change all-cause mortality.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change deaths from any cause.
Peptide
Semaglutide
Outcome
No significant changeAll-cause mortality
Study
n: not reported in source
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Measurements
Odds ratio
0.89 ratio
all-cause mortality
Source sentences
Summary
all-cause mortality [OR=0.89, 95% confidence interval (CI): 0.40-2.00, p = 0.78]
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222202
03HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change all-cause mortality.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change deaths from any cause.
Peptide
Tirzepatide
Outcome
No significant changeAll-cause mortality
Study
n: not reported in source
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Measurements
Odds ratio
0.89 ratio
all-cause mortality
Source sentences
Summary
all-cause mortality [OR=0.89, 95% confidence interval (CI): 0.40-2.00, p = 0.78]
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222203
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change cardiovascular mortality.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change heart-related deaths.
Peptide
Liraglutide
Outcome
No significant changeCardiovascular mortality
Study
n: not reported in source
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Measurements
Odds ratio
0.93 ratio
cardiovascular mortality
Source sentences
Summary
cardiovascular mortality (OR = 0.93, 95% CI: 0.22-4.00, p = 0.92)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222204
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change cardiovascular mortality.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change heart-related deaths.
Peptide
Semaglutide
Outcome
No significant changeCardiovascular mortality
Study
n: not reported in source
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Measurements
Odds ratio
0.93 ratio
cardiovascular mortality
Source sentences
Summary
cardiovascular mortality (OR = 0.93, 95% CI: 0.22-4.00, p = 0.92)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222205
06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change cardiovascular mortality.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change heart-related deaths.
Peptide
Tirzepatide
Outcome
No significant changeCardiovascular mortality
Study
n: not reported in source
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Measurements
Odds ratio
0.93 ratio
cardiovascular mortality
Source sentences
Summary
cardiovascular mortality (OR = 0.93, 95% CI: 0.22-4.00, p = 0.92)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222206
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced worsening heart failure events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to fewer episodes of worsening heart failure.
Peptide
Liraglutide
Outcome
DecreaseWorsening heart failure events
Study
n: not reported in source
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Odds ratio
0.43 ratio
worsening heart failure events
Source sentences
Summary
worsening heart failure events (OR=0.43, 95% CI: 0.30-0.59, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222207
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced worsening heart failure events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to fewer episodes of worsening heart failure.
Peptide
Semaglutide
Outcome
DecreaseWorsening heart failure events
Study
n: not reported in source
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Odds ratio
0.43 ratio
worsening heart failure events
Source sentences
Summary
worsening heart failure events (OR=0.43, 95% CI: 0.30-0.59, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222208
09HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced worsening heart failure events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to fewer episodes of worsening heart failure.
Peptide
Tirzepatide
Outcome
DecreaseWorsening heart failure events
Study
n: not reported in source
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Odds ratio
0.43 ratio
worsening heart failure events
Source sentences
Summary
worsening heart failure events (OR=0.43, 95% CI: 0.30-0.59, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222209
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced body weight.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to weight loss.
Peptide
Liraglutide
Outcome
DecreaseChange in body weight
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−7.9 MD (unit not stated)
change in body weight
Source sentences
Summary
change in body weight (MD = -7.90, 95% CI: -15.44 to -0.35, p = 0.04)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222210
11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced body weight.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to weight loss.
Peptide
Semaglutide
Outcome
DecreaseChange in body weight
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−7.9 MD (unit not stated)
change in body weight
Source sentences
Summary
change in body weight (MD = -7.90, 95% CI: -15.44 to -0.35, p = 0.04)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222211
12HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced body weight.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to weight loss.
Peptide
Tirzepatide
Outcome
DecreaseChange in body weight
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−7.9 MD (unit not stated)
change in body weight
Source sentences
Summary
change in body weight (MD = -7.90, 95% CI: -15.44 to -0.35, p = 0.04)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222212
13HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to a higher heart failure symptom score.
Peptide
Liraglutide
Outcome
IncreaseChange in KCCQ-CSS
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
6.81 MD (unit not stated)
change in KCCQ-CSS
Source sentences
Summary
change in the KCCQ-CSS (MD = 6.81, 95% CI: 6.62-6.99, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222213
14HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to a higher heart failure symptom score.
Peptide
Semaglutide
Outcome
IncreaseChange in KCCQ-CSS
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
6.81 MD (unit not stated)
change in KCCQ-CSS
Source sentences
Summary
change in the KCCQ-CSS (MD = 6.81, 95% CI: 6.62-6.99, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222214
15HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to a higher heart failure symptom score.
Peptide
Tirzepatide
Outcome
IncreaseChange in KCCQ-CSS
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
6.81 MD (unit not stated)
change in KCCQ-CSS
Source sentences
Summary
change in the KCCQ-CSS (MD = 6.81, 95% CI: 6.62-6.99, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222215
16HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists increased the 6-minute walk distance.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to a longer 6-minute walk distance.
Peptide
Liraglutide
Outcome
IncreaseChange in 6-minute walk distance
Study
n: not reported in source
Analysis
Secondary
Outcome group
Exercise and physical function · Whole body
Measurements
Mean difference
15.91 MD (unit not stated)
change in 6-minute walk distance
Source sentences
Summary
change in the 6-minute walk distance (MD = 15.91, 95% CI: 15.36-16.47, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222216
17HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists increased the 6-minute walk distance.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to a longer 6-minute walk distance.
Peptide
Semaglutide
Outcome
IncreaseChange in 6-minute walk distance
Study
n: not reported in source
Analysis
Secondary
Outcome group
Exercise and physical function · Whole body
Measurements
Mean difference
15.91 MD (unit not stated)
change in 6-minute walk distance
Source sentences
Summary
change in the 6-minute walk distance (MD = 15.91, 95% CI: 15.36-16.47, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222217
18HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists increased the 6-minute walk distance.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to a longer 6-minute walk distance.
Peptide
Tirzepatide
Outcome
IncreaseChange in 6-minute walk distance
Study
n: not reported in source
Analysis
Secondary
Outcome group
Exercise and physical function · Whole body
Measurements
Mean difference
15.91 MD (unit not stated)
change in 6-minute walk distance
Source sentences
Summary
change in the 6-minute walk distance (MD = 15.91, 95% CI: 15.36-16.47, p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222218
19HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced B-type natriuretic peptide (BNP) level.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to lower BNP, a heart strain marker.
Peptide
Liraglutide
Outcome
DecreaseChange in BNP level
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
−0.13 MD (unit not stated)
change in BNP level
Source sentences
Summary
change in the BNP level (MD = -0.13, 95% CI: -0.21 to -0.05, p = 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222219
20HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced B-type natriuretic peptide (BNP) level.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to lower BNP, a heart strain marker.
Peptide
Semaglutide
Outcome
DecreaseChange in BNP level
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
−0.13 MD (unit not stated)
change in BNP level
Source sentences
Summary
change in the BNP level (MD = -0.13, 95% CI: -0.21 to -0.05, p = 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222220
21HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists reduced B-type natriuretic peptide (BNP) level.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group were linked to lower BNP, a heart strain marker.
Peptide
Tirzepatide
Outcome
DecreaseChange in BNP level
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
−0.13 MD (unit not stated)
change in BNP level
Source sentences
Summary
change in the BNP level (MD = -0.13, 95% CI: -0.21 to -0.05, p = 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222221
22HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change high-sensitivity C-reactive protein level.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change the inflammation marker hs-CRP.
Peptide
Liraglutide
Outcome
No significant changeChange in hs-CRP level
Study
n: not reported in source
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Mean difference
−16.61 MD (unit not stated)
change in hs-CRP level
Source sentences
Summary
changes in the hs-CRP level (MD = -16.61, 95% CI: -48.53 to 15.31, p = 0.31)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222222
23HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change high-sensitivity C-reactive protein level.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change the inflammation marker hs-CRP.
Peptide
Semaglutide
Outcome
No significant changeChange in hs-CRP level
Study
n: not reported in source
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Mean difference
−16.61 MD (unit not stated)
change in hs-CRP level
Source sentences
Summary
changes in the hs-CRP level (MD = -16.61, 95% CI: -48.53 to 15.31, p = 0.31)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222223
24HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change high-sensitivity C-reactive protein level.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change the inflammation marker hs-CRP.
Peptide
Tirzepatide
Outcome
No significant changeChange in hs-CRP level
Study
n: not reported in source
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Mean difference
−16.61 MD (unit not stated)
change in hs-CRP level
Source sentences
Summary
changes in the hs-CRP level (MD = -16.61, 95% CI: -48.53 to 15.31, p = 0.31)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222224
25HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change left ventricular ejection fraction.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change how well the left ventricle pumps.
Peptide
Liraglutide
Outcome
No significant changeChange in LVEF
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
−0.91 MD (unit not stated)
change in LVEF level
Source sentences
Summary
change in the LVEF level (MD = -0.91, 95% CI: -2.12 to 0.29, p = 0.14)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222225
26HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change left ventricular ejection fraction.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change how well the left ventricle pumps.
Peptide
Semaglutide
Outcome
No significant changeChange in LVEF
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
−0.91 MD (unit not stated)
change in LVEF level
Source sentences
Summary
change in the LVEF level (MD = -0.91, 95% CI: -2.12 to 0.29, p = 0.14)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222226
27HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change left ventricular ejection fraction.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change how well the left ventricle pumps.
Peptide
Tirzepatide
Outcome
No significant changeChange in LVEF
Study
n: not reported in source
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Mean difference
−0.91 MD (unit not stated)
change in LVEF level
Source sentences
Summary
change in the LVEF level (MD = -0.91, 95% CI: -2.12 to 0.29, p = 0.14)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222227
28HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change gastrointestinal adverse events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change stomach and gut side effects.
Peptide
Liraglutide
Outcome
No significant changeGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Odds ratio
0.87 ratio
gastrointestinal adverse events
Source sentences
Summary
gastrointestinal adverse events (OR=0.87, 95% CI: 0.11-7.05, p = 0.90)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222228
29HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change gastrointestinal adverse events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change stomach and gut side effects.
Peptide
Semaglutide
Outcome
No significant changeGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Odds ratio
0.87 ratio
gastrointestinal adverse events
Source sentences
Summary
gastrointestinal adverse events (OR=0.87, 95% CI: 0.11-7.05, p = 0.90)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222229
30HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change gastrointestinal adverse events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change stomach and gut side effects.
Peptide
Tirzepatide
Outcome
No significant changeGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Odds ratio
0.87 ratio
gastrointestinal adverse events
Source sentences
Summary
gastrointestinal adverse events (OR=0.87, 95% CI: 0.11-7.05, p = 0.90)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222230
31HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change serious adverse events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change serious side effects.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Odds ratio
0.63 ratio
serious adverse events
Source sentences
Summary
serious adverse events (OR=0.63, 95% CI: 0.37-1.08, p = 0.09)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4111222231
32HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change serious adverse events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change serious side effects.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Odds ratio
0.63 ratio
serious adverse events
Source sentences
Summary
serious adverse events (OR=0.63, 95% CI: 0.37-1.08, p = 0.09)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4111222232
33HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In obese adults with chronic heart failure, pooled GLP-1 receptor agonists did not significantly change serious adverse events.
In plain wordsIn obese adults with chronic heart failure, GLP-1 drugs as a group did not clearly change serious side effects.
Peptide
Tirzepatide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Odds ratio
0.63 ratio
serious adverse events
Source sentences
Summary
serious adverse events (OR=0.63, 95% CI: 0.37-1.08, p = 0.09)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4111222233

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis.

Summary

Results from this study33

Studies that did not test the peptide alone33

Version history

Subjects

Publication types

Keywords